伊维菌素对轻症COVID-19成人症状缓解时间的影响:随机临床试验
在哥伦比亚卡利单中心进行的双盲随机试验纳入400例轻症COVID-19成人,伊维菌素组(300 μg/kg/天×5天)与安慰剂组症状缓解中位时间分别为10天和12天,HR 1.07(95%CI 0.87-1.32;研究不支持用伊维菌素治疗轻症COVID-19。
要点
- 伊维菌素未显著缩短轻症COVID-19成人症状缓解时间。
- 21天时伊维菌素组82%、安慰剂组79%症状缓解。
- 最常见不良事件为头痛,两组发生率相近。
核心结论
- 在轻症COVID-19成人中,5天伊维菌素疗程相比安慰剂未显著改善症状缓解时间。
- 研究结果不支持使用伊维菌素治疗轻症COVID-19,但可能需要更大规模试验评估其他临床相关结局。
研究设计与样本
- 双盲随机试验,在哥伦比亚卡利单中心开展,通过州卫生部门电子数据库简单随机抽样识别参与者。
- 共纳入476例成人轻症COVID-19患者(症状≤7天,居家或住院),2020年7月15日至11月30日入组,随访至2020年12月21日。
- 主要分析人群400例随机患者(伊维菌素n=200,安慰剂n=200),中位年龄37岁(IQR 29-48),女性231例(58%),398例(99.5%)完成试验。
主要发现
- 第21天时,伊维菌素组82%、安慰剂组79%症状缓解。
- 最常见 solicited 不良事件为头痛,伊维菌素组104例(52%)、安慰剂组111例(56%)报告。
- 最常见严重不良事件为多器官衰竭,共4例(每组2例)。
关键数值与推荐
- 干预:伊维菌素300 μg/kg体重/天,共5天。
- 主要结局:21天随访期内症状缓解时间。
临床怎么用
- 临床不应基于本试验结果使用伊维菌素治疗轻症COVID-19。
- 对轻症COVID-19患者,伊维菌素未显示缩短症状持续时间的获益。
局限性
- 单中心研究,样本量400例,可能不足以评估其他临床相关结局。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. OBJECTIVE: To determine whether ivermectin is an efficacious treatment for mild COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020. INTERVENTION: Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200). MAIN OUTCOMES AND MEASURES: Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected. RESULTS: Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group). CONCLUSION AND RELEVANCE: Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04405843.
引用
- López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33662102. doi:10.1001/jama.2021.3071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。